Drug Profile

BI 1819479

Alternative Names: BI-1819479

Latest Information Update: 12 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim
Class Antifibrotics
Mechanism of Action Lysophospholipase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Idiopathic pulmonary fibrosis
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Idiopathic pulmonary fibrosis

Most Recent Events

04 Aug 2025 Boehringer Ingelheim initiates a phase I trial(In volunteers) (PO) in United Kingdom(PO) (NCT07065617)
04 Jul 2025 Boehringer Ingelheim plans a phase I mass balance, metabolism, and pharmacokinetics trial(In volunteers) (PO) in July 2025 (NCT07065617)
28 Apr 2025 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in Germany (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com